AGM/EGM23 Oct 2026, 05:20 pm
Kilitch Drugs to Sell Entire Stake in Subsidiary for USD 14 Million
AI Summary
Kilitch Drugs India Ltd has announced an Extraordinary General Meeting (EGM) to be held on November 16, 2026, to approve the sale of its entire shareholding in its material subsidiary, Kilitch Estro Biotech PLC, to HarmeeCare Pharmaceuticals. The aggregate consideration for the sale is USD 14,000,000, with Kilitch Drugs receiving USD 12,855,000. The EGM will be conducted via Video Conferencing, with remote e-voting available from November 13 to November 15, 2026. The cut-off date for voting eligibility is November 6, 2026.
Key Highlights
- EGM scheduled for November 16, 2026, to approve subsidiary sale.
- Sale of Kilitch Estro Biotech PLC for USD 14 million.
- Kilitch Drugs to receive USD 12.855 million from the sale.
- Transaction involves selling the entire shareholding in the material subsidiary.
- Meeting to be held via Video Conferencing with remote e-voting.
Price Impact
More from KILITCH